PET分子影像识别进行性核上性麻痹的代谢进展与亚型
研究纳入72例进行性核上性麻痹(PSP)患者和70名对照,另24例PSP患者作为测试集,采用18F-FDG PET及SuStaIn算法分析代谢进展亚型。识别出皮质亚型(早期前额叶代谢减低)和脑干亚型(初始中脑改变),皮质亚型认知损害及多巴胺转运体减低更明显。测试集验证了结果的稳健性和可重复性。
要点
- 基于FDG-PET的SuStaIn算法识别出PSP两种代谢进展亚型:皮质亚型和脑干亚型。
- 皮质亚型表现为早期前额叶代谢减低,脑干亚型表现为初始中脑改变。
- 皮质亚型较脑干亚型认知损害更重、多巴胺转运体减低更明显。
核心结论
- 基于FDG-PET识别出PSP两种时空进展亚型,在代谢模式、纹状体多巴胺摄取和临床特征(尤其认知损害)上存在显著差异。
- 多巴胺能皮质-基底节通路在PSP病理生理中起关键作用,尤其在皮质亚型中,为PSP异质性和个体化治疗提供线索。
研究设计与样本
- 研究纳入72例PSP患者和70名对照,另24例PSP患者作为测试集,均接受FDG-PET、多巴胺转运体(DAT)PET和神经心理学评估。
- 采用SuStaIn算法分析FDG-PET数据,识别进展亚型和序列。
主要发现
- 识别出两种PSP亚型:皮质亚型伴早期前额叶代谢减低,脑干亚型伴初始中脑改变。
- 皮质亚型较脑干亚型表现出更重的认知损害和更明显的DAT减低。
- 测试集证明结果的稳健性和可重复性。
- 通路分析提示多巴胺能皮质-基底节通路破坏对阐明PSP认知和行为损害机制至关重要,并导致两种代谢进展亚型。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Progressive supranuclear palsy (PSP) is a neurodegenerative disorder with diverse clinical presentations that are linked to tau pathology. Recently, Subtype and Stage Inference (SuStaIn) algorithm, an innovative data-driven method, has been developed to model both the spatial-temporal progression and subtypes of disease. This study explores PSP progression using 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging and the SuStaIn algorithm to identify PSP metabolic progression subtypes and understand disease mechanisms. METHODS: The study included 72 PSP patients and 70 controls, with an additional 24 PSP patients enrolled as a test set, undergoing FDG-PET, dopamine transporter (DAT) PET, and neuropsychological assessments. The SuStaIn algorithm was employed to analyze the FDG-PET data, identifying progression subtypes and sequences. RESULTS: Two PSP subtypes were identified: the cortical subtype with early prefrontal hypometabolism and the brainstem subtype with initial midbrain alterations. The cortical subtype displayed greater cognitive impairment and DAT reduction than the brainstem subtype. The test set demonstrates the robustness and reproducibility of the findings. Pathway analysis indicated that disruptions in dopaminergic cortico-basal ganglia pathways are crucial for elucidating the mechanisms of cognitive and behavioral impairment in PSP, leading to the two metabolic progression subtypes. CONCLUSION: This study identified two spatiotemporal progression subtypes of PSP based on FDG-PET imaging, revealing significant differences in metabolic patterns, striatal dopaminergic uptake, and clinical profiles, particularly cognitive impairments. The findings highlight the crucial role of dopaminergic cortico-basal ganglia pathways in PSP pathophysiology, especially in the cortical subtype, providing insights into PSP heterogeneity and potential avenues for personalized treatments.
引用
- Wang H, Wang B, Liao Y, et al. Identification of metabolic progression and subtypes in progressive supranuclear palsy by PET molecular imaging. Eur J Nucl Med Mol Imaging. 2024. PMID: 39438298. doi:10.1007/s00259-024-06954-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。